Werewolf Therapeutics Inc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Werewolf Therapeutics Inc
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Werewolf Therapeutics Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Werewolf Therapeutics Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Werewolf Therapeutics Inc is HOWL:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Werewolf Therapeutics Inc has its primary listing on NASDAQ. You can trade Werewolf Therapeutics Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Werewolf Therapeutics Inc is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Werewolf Therapeutics Inc as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Werewolf Therapeutics Inc.